Business Wire

CyberArk Named a Leader in 2023 Gartner Magic Quadrant for Privileged Access Management

11.9.2023 18:06:00 EEST | Business Wire | Press release

Share

CyberArk (NASDAQ: CYBR), the identity security company, today announced it has been named a Leader in the 2023 Gartner® Magic Quadrant™ for Privileged Access Management.1 CyberArk is recognized in this report for the fifth consecutive time. Additionally, CyberArk is the only vendor positioned as a Leader in both Gartner Magic Quadrant Privileged Access Management (PAM) and Access Management 2 reports.

The CyberArk Identity Security Platform enables organizations to secure all identities – including workforce, IT, developer and non-human – against cyber threats with intelligent privilege controls. With CyberArk, customers have a single, unified platform for identity security that delivers operational efficiencies and faster ROI. Core to the platform are PAM solutions that secure standing, just-in-time and zero standing privileged access across hybrid and multi-cloud environments, and that improve secrets management to significantly reduce the #1 source of cyber risk: credential theft.

“We are extremely proud to be named a Leader by Gartner again. We believe this recognition underscores our commitment and track record of delivering continuous innovation to meet the evolving needs of our customers,” said Matt Cohen, CEO, CyberArk. “In today’s business and threat environment, every identity is a target for attackers. This is why we continue to extend intelligent privilege controls to all identities – human and machine – while developing deep product integrations across our platform, giving security teams the operational control and visibility they need to secure identities across the enterprise.”

CyberArk believes its consistent recognition as a Leader is the result of its focus on core foundational elements, including:

  • Continuous Innovation: CyberArk continues to build upon core strengths in PAM and innovation across its PAM as-a-Service and self-hosted offerings. CyberArk has extended intelligent privilege controls across the entire identity lifecycle, for all types of identities. Recent innovations address emerging use cases for secure, developer-friendly access to public cloud workloads and services. New capabilities include just-in-time privileged access management and low-code and no-code automation workflows that enable automated identity orchestration. CyberArk Secrets Management, an essential part of PAM, is differentiated in its ability to allow organizations to centrally secure, manage and rotate secrets used by the broadest range of application identities. Earlier this year, CyberArk announced expanded secrets management capabilities, new AI-powered policy creation automation for improved endpoint privilege security and the ability for PAM administrators to broker, record and protect native privileged sessions in one-click.
  • Exceptional Customer Experience: Globally, CyberArk provides flexible, closely aligned sales, technical and deployment resources to help customers accelerate time to value. Over the past year, CyberArk introduced new training programs and updates to the CyberArk Blueprint for Identity Security Success, in addition to ongoing complimentary access to resources such as the CyberArk Technical Community and CyberArk Success Blog. According to Gartner Peer Insights™, CyberArk has a 91% “would recommend” rating.3
  • High Performance and Delivery: CyberArk Security Services, together with its global partner network of channel, MSPs, global systems integrators and advisory firms, help many of the world’s largest enterprises design, deploy and optimize PAM and identity security programs. CyberArk continues to nurture strong and consistent growth among its partner community through expanded training and enablement programs. Now, more than ever, CyberArk’s global ecosystem of C3 Alliance technology partners is critical to helping security teams consolidate and maximize existing investments to mitigate emerging risks and address evolving identity security challenges.

To download a complimentary copy of the 2023 Gartner Magic Quadrant for Privileged Access Management visit: https://www.cyberark.com/gartner-2023-mq-pam

1 – Gartner® Magic Quadrant™ for Privileged Access Management, by Felix Gaehtgens, James Hoover, Michael Kelley, Brian Guthrie, Abhyuday Data, 5 September 2023
2 – Gartner® Magic Quadrant for Access Management, by Henrique Teixeira, Abhyuday Data, Michael Kelley, James Hoover, Brian Guthrie, 1 November 2022
3 – Gartner Peer Insights™ (rating as of Aug. 30, 2023; based on past 12 months), https://www.gartner.com/reviews/market/privileged-access-management/vendor/cyberark

Gartner Disclaimers

GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant and Peer Insights are a registered trademark, of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

​Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

About CyberArk

CyberArk (NASDAQ: CYBR) is the global leader in identity security. Centered on intelligent privilege controls, CyberArk provides the most comprehensive security offering for any identity – human or machine – across business applications, distributed workforces, hybrid cloud environments and throughout the DevOps lifecycle. The world’s leading organizations trust CyberArk to help secure their most critical assets. To learn more about CyberArk, visit https://www.cyberark.com, read the CyberArk blogs or follow on LinkedIn, Twitter, Facebook or YouTube.

Copyright © 2023 CyberArk Software. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Carissa Ryan, CyberArk
Email: press@cyberark.com

Highwire PR
Email: cyberark@highwirepr.com

Investor Relations:
Erica Smith, CyberArk
Email: ir@cyberark.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye